Ubs Group Ag Sarepta Therapeutics, Inc. Call Options Transaction History

Ubs Group Ag

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 13, 2024	BUY	$113.33 - $163.85 $7.56 Million - $10.9 Million	66,700 New	66,700 $10.5 Million
Q4 2022 Feb 08, 2023	SELL	$100.86 - $132.13 $2.98 Million - $3.9 Million	-29,500 Reduced 98.01%	600 $77,000
Q3 2022 Nov 10, 2022	BUY	$75.71 - $119.24 $2.23 Million - $3.52 Million	29,500 Added 4916.67%	30,100 $3.33 Million
Q2 2022 Aug 10, 2022	SELL	$62.69 - $88.44 $720,935 - $1.02 Million	-11,500 Reduced 95.04%	600 $45,000
Q2 2020 Jul 31, 2020	SELL	$93.0 - $171.7 $120,900 - $223,209	-1,300 Reduced 9.7%	12,100 $1.94 Million
Q3 2017 Nov 14, 2017	SELL	$35.73 - $47.15 $7 Million - $9.24 Million	-195,900 Reduced 93.6%	13,400 $608,000
Q2 2017 Aug 14, 2017	BUY	N/A	195,900 Added 1461.94%	209,300 $7.06 Million
Q1 2017 Nov 14, 2017	BUY	N/A	13,400	13,400 $397,000

529

84.2M

2.06M

1.52M

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $10.4B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.